Effect of nucleoside and nucleotide reverse transcriptase inhibitors of HIV on endogenous nucleotide pools

Antiviral Therapy

Volumn 13, Issue 6, 2008, Pages 789-797

  Vela, Jennifer E ^a   Miller, Michael D ^a   Rhodes, Gerald R ^a   Ray, Adrian S ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 7 [1 (2 FLUOROPHENYL) 2 HYDROXYETHYL] 3,5 DIHYDRO 4H PYRROLO[3,2 D]PYRIMIDIN 4 ONE; ABACAVIR; ANTIMETABOLITE; ANTIRETROVIRUS AGENT; DEOXYCYTIDINE PHOSPHATE DEAMINASE; DEOXYGUANOSINE; DEOXYGUANOSINE TRIPHOSPHATE; DEOXYRIBONUCLEOSIDE TRIPHOSPHATE; DIDANOSINE; HYDROXYUREA; LAMIVUDINE; METHOTREXATE; NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITOR; PNP 405; PURINE NUCLEOSIDE PHOSPHORYLASE; PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; THYMIDINE; THYMIDINE TRIPHOSPHATE; THYMINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; LIQUID CHROMATOGRAPHY; LYMPHOCYTE CULTURE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE;

ANTIMETABOLITES; CELL LINE, TUMOR; CHROMATOGRAPHY, LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MASS SPECTROMETRY; NUCLEOSIDES; NUCLEOTIDES; REVERSE TRANSCRIPTASE INHIBITORS; T-LYMPHOCYTES;

EID: 53149133921     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Ray AS. Intracellular interactions between nucleos(t)ide inhibitors of HIV reverse transcriptase. AIDS Rev 2005; 7:113-125.
2. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987; 317:192-197.
3. Gallant JE, DeJesus E, Arrihas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz; for HIV. N Engl J Med 2006; 354:251-260.
4. McKee EE, Bentley AT, Hatch M, Gingerich J, Susan-Resiga D. Phosphorylation of thymidine and AZT in heart mitochondria: elucidation of a novel mechanism of AZT cardiotoxicity. Cardiovasc Toxicol 2004; 4:155-167.
5. Lynx MD, McKee EE. 3′-Azido-3′-deoxythymidine (AZT) is a competitive inhibitor of thymidine phosphorylation in isolated rat heart and liver mitochondria. Biochem Pharmacol 2006; 72:239-243.
6. Lynx MD, Bentley AT, McKee EE. 3′-Azido-3′-deoxythymidine, (AZT) inhibits thymidine phosphorylation in isolated rat liver mitochondria: a possible mechanism of AZT hepatotoxicity. Biochem Pharmacol 2006; 71:1342-1348.
7. Sommadossi JP, Carlisle R, Zhou Z. Cellular pharmacology of 3′-azido-3′-deoxythymidine with evidence of incorporation into DNA of human bone marrow cells. Mol Pharmacol 1989; 36:9-14.
8. Vazquez-Padua MA, Starnes MC, Cheng YC. Incorporation of 3′-azido-3′-deoxythymidine into cellular DNA and its removal in a human leukemic cell line. Cancer Commun 1990; 2:55-62.
9. Bridges EG, Faraj A, Sommadossi JP. Inhibition of mammalian DNA polymerase-associated 3′ to 5′ exonuclease activity by 5′-monophosphates of 3′-azido-3′-deoxythymidine and 3′-amino-3′-deoxythymidine. Biochem Pharmacol 1993; 45:1571-1576.
10. Cretton EM, Sommadossi JR Reduction of 3′-azido-2′,3′-dideoxymideosides to their 3′-amino metabolite is mediated by cytochrome P-450 and NADPH-cytochrome P-450 reductase in rat liver microsomes. Drug Metab Dispos 1993; 21:946-950.
11. Sales SD, Hoggard PG, Sunderland D, Khoo S, Hart CA, Back DJ. Zidovudine phosphorylation and mitochondrial toxicity in vitro. Toxicol Appl Pharmacol 2001; 177:54-58.
12. Furman PA, Fyfe JA, St Clair MH, et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the Y-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A 1986; 83:8333-8337.
13. Bzowska A, Kulikowska E, Shugar D. Purine nucleoside phosphorylases: properties, functions, and clinical aspects. Pharmacol Ther 2000; 88:349-425.
14. Ray AS, Olson L, Fridland A. Role of purine nucleoside p hosphorylase in interactions between 2′,3′-dideoxyinosine and allogerinol, ganciclovir, or tenofovir. Antimicrob Agents ther 2004; 48:1089-1095.
15. Kakuda TN, Anderson PL, Becker SL. CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related. AIDS 2004; 18:2442-2444.
16. Bantia S, Ananth SL, Parker CD, Horn LL, Upshaw R. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor-BCX-1777. Int Immunopharmacol 2003; 3:879-887.
17. Negredo E, Molto J, Burger D, et al. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS 2004; 18:459-463.
18. + T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS 2005; 19:569-575.
19. van Leeuwen R, Katlama C, Murphy RL, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 2003; 17:987-999.
20. Gerstoft J, Kirk O, Obel N, et al. Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. AIDS 2003; 17:2045-2052.
21. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing repimens for the initial treatment of HIV-1 infection. N Eng J Med 2004; 350:1850-1861.
22. Winston A, Pozniak A, Mandalia S, Gazzard B, Pillay D, Nelson M. Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase. AIDS 2004; 18:949-951.
23. Jemsek Hutcherson P, Harper E. Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. 11th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2004, San Francisco, CA, USA. Abstract 51.
24. Gallant JE, Rodriguez AE, Weinberg WG, et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 2005; 192:1921-1930.
25. Panel on Antiretroviral Guidelines for Adults and Adolescents. dolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. (Updated 29 January 2008. Accessed 24 April 2008.) Available from http://aidsinfo.nih.gov/ContentFiles/AdultandAdeloscentGL.pdf
26. Prashad M, Hat D, Chen L, Kim HY, Repic O, Blacklock TJ. An efficient and large-scale enantioselective synthesis of PNP405: a purine nucleoside phosphorylase inhibitor. J Org Chem 2002; 67:6612-6617.
27. Vela E, Olson LY, Huang A, Fridland A, Ray AS. Simultaneous quantitation of the nucleotide analog adefovir, its phosphorylated anabolites and 2′-deoxyadenosine triphosyhate by ion-pairing LC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 848:335-343.
28. Traut TW. Physiological concentrations of purines and pyrimidines. Mol Cell Biochem 1994; 140:1-22.
29. Mitsuya H, Weinhold KJ, Furman PA, et al. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cyropathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A 1985; 82:7096-7100.
30. Fridland A, Connelly MC, Ashmun R. Relationship of deoxynucleotide changes to inhibition of DNA synthesis induced by the antiretroviral agent 3′-azido-3′-deoxythymidine and release of its monophosphate by human lymphoid cells (CCRF-CEM). Mol Pharmacol 1990; 37:665-670.
31. Nicander B, Reichard P. Relations between synthesis of deoxyribonucleotides and DNA replication in 3T6 fibroblasts. J Biol Chem 1985; 260:5376-5381.
32. Kramata P, Downey KM. 9-(2-phosphonylmethoxyethyl) derivatives of purine nucleotide analogs: A comparison of their metabolism and interaction with cellular DNA synthesis. Mol Pharmacol 1999; 56:1262-1270.
33. Huang P, Farquhar D, Plunkett W. Selective action of 3′-azido-3′-deoxythymidine 5′-triphosphate on viral reverse transcriptases and human DNA polymerases. J Biol Chem 1990; 265:11914-11918.
34. Copeland WC, Chen MS, Wang TS. Human DNA polymerases alpha and beta are able to incorporate anti-HIV deoxynucleotides into DNA. J Biol Chem 1992; 267:21459-21464.
35. Nickel W, Austermann S, Bialek G, Grosse E, Interactions of azidothymidine triphosphate with the cellular DNA polymerases alpha, delta, and epsilon and with DNA primase. J Biol Chem 1992; 267:848-854.
36. Johnson AA, Ray AS, Hanes J, et al. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem 2001; 276:40847-40857.
37. Liou JY, Krishnan P, Hsieh CC, Dutschman GE, Cheng YC. Assessment of the effect of phosphorylated metabolites of anti-human immunodeficiency virus and anti-hepatitis B virus pyrimidine analogs on the behavior of human deoxycytidylate deaminase. Mol Pharmacol 2003; 63:105-110.
38. Lewandowicz A, Tyler PC, Evans GB, Furneaux RH, Schramm VL. Achieving the ultimate physiological goal in transition state analogue inhibitors for purine nucleoside phosphorylase. J Biol Chem 2003; 278:31465-31468.
39. + peripheral blood T cells following treatment with tenofovir +/- abacavir +/- lamivudine. XV International Drug Resistance Workshop: Basic Principles and Clinical Implications. 13-17 June 2006, Sitges, Spain. Abstract 146.
40. Robbins BL, Srinivas RV, Kim C, Bischofberger N, Fridland A. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl) adenine (PMPA), bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother 1998; 42:612-617.
41. Barditch-Crovo P, Deeks SG, Collier A, et al. Phase I/ II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001; 45:2733-2739.
42. Robbins BL, Wilcox CK, Fridland A, Rodman JH. Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells. Pharmacotherapy 2003; 23:695-701.
43. Pruvost A, Negredo E, Benech H, et al. Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2005; 49:1907-1914.
44. Ray AS, Myrick F, Vela JE, et al. Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine. Antivir Ther 2005; 10:451-457.
45. Hawkins T, Veikley W, St Claire RL, III, Guyer B, Clark N, Kearney BP. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr 2005; 39:406-411.
46. Staszewski S, Keiser P, Montaner J, et al. Abacavirlamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA 2001; 285:1155-1163.
47. Roge BT, Katzenstein TL, Obel N, et al. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antivir, Ther 2003; 8:173-182.
48. DART Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 2006; 20:1391-1399.
49. Moyle G, Higgs C, Teague A, et al. An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy. Antivir Ther 2006; 11:73-78.